Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Lopez-Muniz, JIC; Merino, LD; Gregori, JG; Duenas, EM; Oliveira, M; Palmer, MAS; Lopez, IA; Novoa, SA; Ezquerra, MB; Cobo, SLT.

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2019; 21(1): 31-45 Nº de citas: 13 [doi:10.1007/s12094-018-02010-w]

Di Leo, A; O'Shaughnessy, J; Sledge GW Jr; Martin, M; Lin, Y; Frenzel, M; Hardebeck, MC; Smith, IC; Llombart-Cussac, A; Goetz, MP; Johnston, S.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

Npj Breast Cancer. 2018; 4: 41-41 Nº de citas: 51 [doi:10.1038/s41523-018-0094-2]

Caries, J; Castellano, D; Mendez-Vidal, MJ; Mellado, B; Saez, MI; del Alba, AG; Perez-Gracia, JL; Jimenez, J; Suarez, C; Sepulveda, JM; Manneh, R; Porras, I; Lopez, C; Morales-Barrera, R; Arranz, JA.

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

CLINICAL GENITOURINARY CANCER. 2018; 16(6): 1133-1139 Nº de citas: 14 [doi:10.1016/j.clgc.2018.07.013]

Templeton, AJ; Rodriguez-Lescure, A; Ruiz, A; Alba, E; Calvo, L; Ruiz-Borrego, M; Santaballa, A; Rodriguez, CA; Crespo, C; Ramos, M; Gracia-Marco, JM; Lluch, A; Alvarez, I; Casas, MI; Sanchez-Arago, M; Caballero, R; Carrasco, E; Amir, E; Martin, M; Ocana, A; GEICAM Study Investigators.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(12): 1548-1556 Nº de citas: 11 [doi:10.1007/s12094-018-1885-5]

Sharma, P; Lopez-Tarruella, S; Garcia-Saenz, JA; Khan, QJ; Gomez, HL; Prat, A; Moreno, F; Jerez-Gilarranz, Y; Barnadas, A; Picornell, AC; del Monte-Millan, M; Gonzalez-Rivera, M; Massarrah, T; Pelaez-Lorenzo, B; Palomero, MI; González Del Val R; Cortes, J; Fuentes-Rivera, H; Morales, DB; Marquez-Rodas, I; Perou, CM; Lehn, C; Wang, YY; Klemp, JR; Mammen, JV; Wagner, JL; Amin, AL; O'Dea, AP; Heldstab, J; Jensen, RA; Kimler, BF; Godwin, AK; Martin, M.

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

CLINICAL CANCER RESEARCH. 2018; 24(23): 5820-5829 Nº de citas: 90 [doi:10.1158/1078-0432.CCR-18-0585]

Fernandez, A; Salgado, M; Garcia, A; Buxo, E; Vera, R; Adeva, J; Jimenez-Fonseca, P; Quintero, G; Llorca, C; Canabate, M; Lopez, LJ; Munoz, A; Ramirez, P; Gonzalez, P; Lopez, C; Reboredo, M; Gallardo, E; Sanchez-Canovas, M; Gallego, J; Guillen, C; Ruiz-Miravet, N; Navarro-Perez, V; De la Camara, J; Ales-Diaz, I; Pazo-Cid, RA; Carmona-Bayonas, A.

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

BMC CANCER. 2018; 18: 1185-1185 Nº de citas: 23 [doi:10.1186/s12885-018-5101-3]

Gazzah, A; Boni, V; Soria, JC; Calles, A; Even, C; Doger, B; Mahjoubi, L; Bahleda, R; Ould-Kaci, M; Esler, A; Nazabadioko, S; Calvo, E.

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours

EUROPEAN JOURNAL OF CANCER. 2018; 104: 1-8 Nº de citas: 11 [doi:10.1016/j.ejca.2018.07.011]

Fogelman, D; Cubillo, A; Garcia-Alfonso, P; Miron, MLL; Nemunaitis, J; Flora, D; Borg, C; Mineur, L; Vieitez, JM; Cohn, A; Saylors, G; Assad, A; Switzky, J; Zhou, L; Bendell, J.

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

Cancer Medicine. 2018; 7(11): 5382-5393 Nº de citas: 34 [doi:10.1002/cam4.1703]

Garcia-Alfonso, P; Benavides, M; Falco, E; Munoz, A; Gomez, A; Sastre, J; Rivera, F; Montagut, C; Salgado, M; Lopez-Ladron, A; Lopez, R; de Mena, IR; Duran, G; Aranda, E.

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

ONCOLOGIST. 2018; 23(11): 1271 Nº de citas: 8 [doi:10.1634/theoncologist.2018-0316]

Hodi, FS; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Cowey, CL; Lao, CD; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Hill, A; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, JD.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

LANCET ONCOLOGY. 2018; 19(11): 1480-1492 Nº de citas: 1141 [doi:10.1016/S1470-2045(18)30700-9]

Ruiz-Pinto, S; Martin, M; Pita, G; Caronia, D; de la Torre-Montero, JC; Moreno, LT; Moreno, F; Garcia-Saenz, JA; Benitez, J; Gonzalez-Neira, A.

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

PHARMACOGENETICS AND GENOMICS. 2018; 28(11): 245-250 Nº de citas: 5 [doi:10.1097/FPC.0000000000000354]

Paumard-Hernandez, B; Calvete, O; Perez, L; Tejero, H; Al-Shahrour, F; Pita, G; Barroso, A; Trivino, J; Urioste, M; Valverde, C; Billalabeitia, E; Quiroga, V; Moreno, JF; Aramburo, A; Lopez, C; Maroto, P; Sastre, J; Fita, MJ; Duran, I; Lorenzo-Lorenzo, I; Iranzo, P; del Muro, X; Ros, S; Zambrana, F; Autran, A; Benitez, J.

Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

INTERNATIONAL JOURNAL OF CANCER. 2018; 143(8): 1954-1962 Nº de citas: 18 [doi:10.1002/ijc.31604]

Salvador-Martin, S; Garcia-Gonzalez, X; Garcia, MI; Blanco, C; Garcia-Alfonso, P; Robles, L; Gravalos, C; Pachon, V; Longo, F; Martinez, V; Sanjurjo-Saez, M; Lopez-Fernandez, LA.

Clinical utility of ABCB1 for preventing toxicity in treatment with irinotecan

PHARMACOLOGICAL RESEARCH. 2018; 136: 133-139 Nº de citas: 19 [doi:10.1016/j.phrs.2018.08.026]

Collado-Borrell, R; Escudero-Vilaplana, V; Calles, A; Garcia-Martin, E; Marzal-Alfaro, B; Gonzalez-Haba, E; Herranz-Alonso, A; Sanjurjo-Saez, M.

Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey

JOURNAL OF MEDICAL INTERNET RESEARCH. 2018; 20(10): Nº de citas: 35 [doi:10.2196/11006]

Martin, M; de la Torre-Montero, JC; Lopez-Tarruella, S; Pinilla, K; Casado, A; Fernandez, S; Jerez, Y; Puente, J; Palomero, I; del Val, RG; del Monte-Millan, M; Massarrah, T; Vila, C; Garcia-Paredes, B; Garcia-Saenz, JA; Lluch, A.

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

BREAST CANCER RESEARCH AND TREATMENT. 2018; 171(3): 627-634 Nº de citas: 24 [doi:10.1007/s10549-018-4855-2]

Ettl, J; Quek, RGW; Lee, KH; Rugo, HS; Hurvitz, S; Goncalves, A; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Markova, D; Bhattacharyya, H; Hannah, AL; Eiermann, W; Blum, JL; Litton, JK.

Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial

ANNALS OF ONCOLOGY. 2018; 29(9): 1939-1947 Nº de citas: 110 [doi:10.1093/annonc/mdy257]

Agnelli, G; Becattini, C; Bauersachs, R; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Munoz, A; de Sousa, JA; Torbicki, A; Verso, M; Vescovo, G; Caravaggio Study Investigators.

Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study

THROMBOSIS AND HAEMOSTASIS. 2018; 118(9): 1668-1678 Nº de citas: 104 [doi:10.1055/s-0038-1668523]

Von Hoff, DD; Rasco, DW; Heath, EI; Munster, PN; Schellens, JHM; Isambert, N; Le Tourneau, C; O'Neill, B; Mathijssen, RHJ; Lopez-Martin, JA; Edenfiele, WJ; Martin, M; LoRusso, PM; Bray, GL; DiMartino, J; Nguyen, A; Liu, KJ; Laille, E; Bendell, JC.

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

CLINICAL CANCER RESEARCH. 2018; 24(17): 4072-4080 Nº de citas: 22 [doi:10.1158/1078-0432.CCR-17-3716]